Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Kymera Therapeutics, Inc. KYMR NASDAQ

NASDAQ Global Market • Healthcare • Biotechnology • US • USD

SharesGrow Score
45/100
1/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$117.31
+31.8%

Kymera Therapeutics, Inc. (KYMR) is a Biotechnology company in the Healthcare sector, currently trading at $89.00. It has a SharesGrow Score of 45/100, indicating a mixed investment profile with 1 out of 7 criteria passed.

Analyst consensus target is KYMR = $117 (+31.8% upside).

Valuation: KYMR trades at a trailing Price-to-Earnings (P/E) of -23.7 (S&P 500 average ~25).

Financials: revenue is $39M, +3.7%/yr average growth. Net income is $311M (loss), growing at -29.4%/yr. Net profit margin is -794.4% (negative). Gross margin is 100% (+6.4 pp trend).

Balance sheet: total debt is $82M against $1.6B equity (Debt-to-Equity (D/E) ratio 0.05, conservative). Current ratio is 10.47 (strong liquidity). Debt-to-assets is 4.7%. Total assets: $1.7B.

Analyst outlook: 23 / 26 analysts rate KYMR as buy (88%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value 54/100 (Partial), Growth 30/100 (Fail), Past 0/100 (Fail), Health 67/100 (Partial), Moat 62/100 (Partial), Future 94/100 (Pass), Income 10/100 (Fail).

$117.31
▲ 31.81% Upside
Average Price Target
Based on 26 Wall Street analysts offering 12-month price targets for Kymera Therapeutics, Inc., the average price target is $117.31, with a high forecast of $138.00, and a low forecast of $90.00.
Highest Price Target
$138.00
Average Price Target
$117.31
Lowest Price Target
$90.00

KYMR SharesGrow Score Overview

53/100
SharesGrow Score
Mixed signals — some strengths
View full scorecard →
VALUE 54/100
Valuation — P/E, PEG, Forward PEG
GROWTH 30/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 67/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 62/100
Gross margin is + market cap
FUTURE 94/100
Analyst outlook — as buy
INCOME 10/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — KYMR

~
VALUE Partial
54/100
KYMR trades at a trailing Price-to-Earnings (P/E) of -23.7 (S&P 500 average ~25). Forward PEG -1.95 — Peter Lynch undervalued (≤1.0). Trailing PEG 8.49. Analyst consensus target is $117, implying +31.5% from the current price $89. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✗
GROWTH Fail
30/100
KYMR: +3.7%/yr revenue is, -29.4%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
~
HEALTH Partial
67/100
Balance sheet KYMR: Debt-to-Equity (D/E) ratio 0.05 (conservative), Current ratio is 10.47 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
~
MOAT Partial
62/100
KYMR: Gross margin is 100% (+6.4 pp trend), $7B market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 62/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
94/100
Analyst outlook: 23 / 26 analysts rate KYMR as buy (88%). Analyst consensus target is $117 (+31.5% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
✗
INCOME Fail
10/100
KYMR: Net profit margin is -794.4%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range19.445-103
Volume377.15K
Avg Volume (30D)738.02K
Market Cap$7.27B
Beta (1Y)2.29
Share Statistics
EPS (TTM)-3.69
Shares Outstanding$84.39M
IPO Date2020-08-21
Employees208
CEONello Mainolfi
Financial Highlights & Ratios
Revenue (TTM)$39.2M
Gross Profit$39.2M
EBITDA$-303.06M
Net Income$-311.4M
Operating Income$-349.4M
Total Cash$848.28M
Total Debt$82.25M
Net Debt$-274.76M
Total Assets$1.74B
Price / Earnings (P/E)-24.1
Price / Sales (P/S)185.36
Analyst Forecast
1Y Price Target$119.00
Target High$138.00
Target Low$90.00
Upside+33.7%
Rating ConsensusBuy
Analysts Covering26
Buy 88% Hold 12% Sell 0%
Price Target Summary
Company Info
CountryUS
ExchangeNASDAQ Global Market
CurrencyUSD
ISINUS5015751044

Price Chart

Track all markets on TradingView
KYMR
Kymera Therapeutics, Inc. ↗  ·  NASDAQ Global Market
Healthcare • Biotechnology
19.45 52WK RANGE 103.00

People Also View

RVMD
RVMD
Revolution Medicines, Inc.
$152.54
+3.76%
 EWTX
EWTX
Edgewise Therapeutics, Inc.
$33.70
+1.63%
 AGIO
AGIO
Agios Pharmaceuticals, Inc.
$34.45
+3.45%
 MLYS
MLYS
Mineralys Therapeutics, Inc.
$30.42
+11.35%
 NRIX
NRIX
Nurix Therapeutics, Inc.
$16.97
+4.11%
 GLUE
GLUE
Monte Rosa Therapeutics, Inc.
$18.23
+4.17%
 CGEM
CGEM
Cullinan Oncology, Inc.
$14.95
+4.18%
 STTK
STTK
Shattuck Labs, Inc.
$7.17
+5.75%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message